MAPT and Alzheimer disease: New drug design and development based on blocking Aβ-promoted tau seeding by inhibiting Aβ-oligomer–cell interactions [55], preventing tau seed uptake, or a combination of both could present new opportunities with greater promise to delay or even halt AD progression.